|
|
|
|
LEADER |
01328nam a2200253 u 4500 |
001 |
EB002010808 |
003 |
EBX01000000000000001173707 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
220201 r ||| eng |
100 |
1 |
|
|a Brett, Kendra
|
245 |
0 |
0 |
|a Direct observational therapy for the treatment of tuberculosis
|h Elektronische Ressource
|b review of clinical evidence and guidelines
|c Kendra Brett, Melissa Severn
|
250 |
|
|
|a Version: 1.0
|
260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, November 24, 2020
|
300 |
|
|
|a 1 PDF file (51 pages)
|b illustration
|
505 |
0 |
|
|a Includes bibliographical references
|
700 |
1 |
|
|a Severn, Melissa
|e [author]
|
710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK567074
|3 Volltext
|
082 |
0 |
|
|a 610
|
520 |
|
|
|a The purpose of the current report is to summarize and critically appraise the relevant evidence regarding the provision of DOT for the treatment of TB. Additionally, evidence-based guidelines with recommendations regarding the use of DOT for the treatment of TB will be reviewed
|